SOX2 and prostate carcinoma: Consistent with many reports linking SOX2 expression to increases in metastasis, a strong connection between SOX2 and epithelial-mesenchymal transition (EMT) has been established in many tumor types, including colorectal, esophageal (ESCC), laryngeal, pancreatic, lung (NSCLC), gastric, breast, and prostate cancer [54, 57–63].